Bioequivalence and Bioavailability Forum 23:36 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

What's the problem? [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-05-17 12:07  - Posting: # 17367
Views: 14,334

Hi DM,

» It would be interesting to study the within study variation for the same compound in the same unit to understand which is the main source of variability. Although I understand the point of El Maestro about assay sensitivity, I don't think that could be pointed as a cause for a study which presented high variability when other studies reported low variability. I understand the approach to highly variable drugs, when the drug is actually highly variable per se and not due to study conduct or assay sensibility.

Then it all comes back to one of Helmut's favourite hobbies, calculation of confidence intervals for variabilities. I think the conclusion generally is that perhaps the drug is highly variable and perhaps it isn't.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,923 posts in 4,039 threads, 1,284 registered users;
online 15 (1 registered, 14 guests [including 9 identified bots]).

Whenever you find that you are on the side of the majority,
it is time to pause & reflect.    Mark Twain

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed